A new trading day began on Tuesday, with Kymera Therapeutics Inc (NASDAQ: KYMR) stock price up 3.05% from the previous day of trading, before settling in for the closing price of $47.16. KYMR’s price has ranged from $19.44 to $53.27 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 74.20% over the past five years. Meanwhile, its annual earnings per share averaged -15.81%. With a float of $53.22 million, this company’s outstanding shares have now reached $65.11 million.
Let’s look at the performance matrix of the company that is accounted for 188 employees. In terms of profitability, gross margin is 100.0%, operating margin of -472.5%, and the pretax margin is -409.07%.
Kymera Therapeutics Inc (KYMR) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Kymera Therapeutics Inc is 18.27%, while institutional ownership is 95.94%. The most recent insider transaction that took place on Jun 03 ’25, was worth 245,186. In this transaction Director of this company sold 5,000 shares at a rate of $49.04, taking the stock ownership to the 0 shares. Before that another transaction happened on Jun 03 ’25, when Company’s Director sold 12,000 for $46.10, making the entire transaction worth $553,200. This insider now owns 0 shares in total.
Kymera Therapeutics Inc (KYMR) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -15.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.41% during the next five years compared to -26.36% drop over the previous five years of trading.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Here are Kymera Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 53.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.86 in one year’s time.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics Inc (NASDAQ: KYMR) saw its 5-day average volume 1.04 million, a positive change from its year-to-date volume of 0.76 million. As of the previous 9 days, the stock’s Stochastic %D was 89.93%. Additionally, its Average True Range was 3.01.
During the past 100 days, Kymera Therapeutics Inc’s (KYMR) raw stochastic average was set at 95.48%, which indicates a significant increase from 93.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 158.57% in the past 14 days, which was higher than the 94.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.21, while its 200-day Moving Average is $39.51.
